Daily Papers

When engaging in collaborative tasks, humans efficiently exploit the semantic structure of a conversation to optimize verbal and nonverbal interactions. But in recent "language to code" or "language to action" models, this information is lacking. We show how incorporating the prior discourse and nonlinguistic context of a conversation situated in a nonlinguistic environment can improve the "language to action" component of such interactions. We fine tune an LLM to predict actions based on prior context; our model, NeBuLa, doubles the net-action F1 score over the baseline on this task of Jayannavar et al.(2020). We also investigate our model's ability to construct shapes and understand location descriptions using a synthetic dataset.

Estimating the impact of continuous treatment variables (e.g., dosage amount) on binary outcomes presents significant challenges in modeling and estimation because many existing approaches make strong assumptions that do not hold for certain continuous treatment variables. For instance, traditional logistic regression makes strong linearity assumptions that do not hold for continuous treatment variables like time of initiation. In this work, we propose a semiparametric regression framework that decomposes effects into two interpretable components: a prognostic score that captures baseline outcome risk based on a combination of clinical, genetic, and sociodemographic features, and a treatment-interaction score that flexibly models the optimal treatment level via a nonparametric link function. By connecting these two parametric scores with Nadaraya-Watson regression, our approach is both interpretable and flexible. The potential of our approach is demonstrated through numerical simulations that show empirical estimation convergence. We conclude by applying our approach to a real-world case study using the International Warfarin Pharmacogenomics Consortium (IWPC) dataset to show our approach's clinical utility by deriving personalized warfarin dosing recommendations that integrate both genetic and clinical data, providing insights towards enhancing patient safety and therapeutic efficacy in anticoagulation therapy.